Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.530
Filtrar
1.
J Headache Pain ; 21(1): 38, 2020 Apr 25.
Artigo em Inglês | MEDLINE | ID: mdl-32334535

RESUMO

The world is currently dominated by the Corona Virus Disease 2019 (COVID-19) pandemic. Besides the obvious concerns about limitation of virus spread and providing the best possible care to infected patients, a concomitant concern has now arisen in view of a putative link between the use of certain drugs, such as Renin-Angiotensin System (RAS) inhibitors and ibuprofen, and an increased risk for COVID-19 infection. We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.


Assuntos
Antagonistas de Receptores de Angiotensina/efeitos adversos , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Infecções por Coronavirus/patologia , Cefaleia/tratamento farmacológico , Ibuprofeno/efeitos adversos , Pneumonia Viral/patologia , Antagonistas de Receptores de Angiotensina/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Betacoronavirus , Humanos , Ibuprofeno/uso terapêutico , Pandemias , Peptidil Dipeptidase A/metabolismo , Sistema Renina-Angiotensina , Fatores de Risco , Regulação para Cima/efeitos dos fármacos
2.
Drug Ther Bull ; 58(5): 69, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-32234728

RESUMO

Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers' attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned.


Assuntos
Anti-Inflamatórios não Esteroides , Betacoronavirus , Infecções por Coronavirus/tratamento farmacológico , Pneumonia Viral/tratamento farmacológico , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/uso terapêutico , Europa (Continente) , Humanos , Ibuprofeno/efeitos adversos , Ibuprofeno/uso terapêutico , Agências Internacionais , Pandemias
3.
s.l; RedARETS; mar. 2020.
Não convencional em Espanhol | LILACS, BRISA/RedTESA | ID: biblio-1094946

RESUMO

CONTEXTO: En los últimos años, nuevas infecciones por coronavirus han surgido periódicamente en varios países del mundo. El coronavirus del síndrome respiratorio agudo severo (SARS-CoV) ocurrió en 2002, infectando a 8422 personas y causando 916 muertes durante la epidemia. El síndrome de coronavirus del Medio Oriente (MERS ­ CoV) se identificó por primera vez en 2012. Un total de 2499 casos fueron confirmados por laboratorio de MERS. A finales de 2019, un nuevo coronavirus surgió en Wuhan (China) y se extendió rápidamente. El patógeno se confirmó y fue nombrado oficialmente enfermedad por coronavirus ­ 19 (COVID ­ 19) por la Organización Mundial de la Salud (OMS). El cuadro clínico de la infección por COVID-19 cursa con fiebre en un gran porcentaje de los casos (>80%), siendo esta uno de los criterios diagnósticos establecidos desde el inicio del brote en China1 , aceptados por la OMS y por todos los países incluyendo Argentina. Desde hace unos años se han reportado efectos adversos relacionados con el uso de ibuprofeno en infecciones respiratorias. El Ministerio de Salud de Francia y agencia regulatoria de ese país emitieron un alerta sobre este tema, observando que el uso de ibuprofeno podría asociarse a una peor evolución clínica. TECNOLOGÍA: El ibuprofeno es un AINE derivado del ácido propiónico. Es útil como analgésico-antipirético y presenta además actividad antiinflamatoria. El paracetamol o acetaminofén es un metabolito activo de la fenacetina. Es útil como analgésico-antipirético pero tiene baja actividad antiinflamatoria. BÚSQUEDA Y ANÁLISIS DE LA EVIDENCIA CIENTÍFICA: Se realizó una búsqueda no sistemática de bibliografía científica priorizando la inclusión de revisiones sistemáticas y metaanálisis, evaluaciones de tecnologías sanitarias e informes de seguridad, estudios de casos y controles y de cohortes prospectivas y retrospectivas, y Guías de Práctica Clínica basadas en la evidencia. RESULTADOS: Una revisión sistemática del año 2009 sobre estudios en niños concluye que el ibuprofeno, el paracetamol y el placebo tienen perfiles de tolerabilidad y seguridad similares en términos de síntomas gastrointestinales, asma y efectos adversos renales. Si bien los datos del estudio pueden no reflejar el uso de estos fármacos sin receta, los resultados son relevantes en relación al perfil de seguridad del tratamiento general con ibuprofeno o paracetamol en niños. Una revisión en pacientes pediátricos 4 concluye que la terapia combinada o alterna resultó más efectiva que la monoterapia para reducir la temperatura corporal. Sin embargo, el beneficio parecía modesto y probablemente no clínicamente relevante. El efecto sobre la incomodidad del niño y el número de dosis de medicación también fue modesto. Las evidencias no son lo suficientemente sólidas como para alentar el paracetamol y el ibuprofeno combinados o alternos en lugar de la monoterapia para tratar a los niños con fiebre, lo que refuerza la recomendación actual de la mayoría de las guías internacionales. Dos estudios randomizados en personas con infecciones respiratorias mostraron hallazgos similares a los estudios observaciones sobre mayores complicaciones en la evolución en quienes recibieron ibuprofeno comparado con paracetamol . Otro estudio registrado en Cochrane Library sobre niños tratados con ibuprofeno o paracetamol y uno más reciente denominado PITCH trial evaluó la asociación de ibuprofeno más paracetamol comparado con paracetamol solo 8 mostraron mayor tasa de eventos adversos con ibuprofeno. Los estudios observacionales pueden brindar información muy importante para establecer la seguridad de intervenciones. En niños se observó una posible asociación entre el uso de ibuprofeno y mayor riesgo de complicaciones pleuropulmonares como el empiema. También en adultos hay reportes sobre potenciales mayores complicaciones. Hay estudios que encontraron mayor riesgo de infarto en pacientes que cursaban una infección respiratoria aguda11 , y otros lo asociaron con mayor riesgo de ACV durante estas infecciones. RECOMENDACIÓN: En favor de la utilización de paracetamol en lugar de ibuprofeno como agente antipirético en el contexto de pandemia por COVID-19.


Assuntos
Ibuprofeno/efeitos adversos , Infecções por Coronavirus/tratamento farmacológico , Acetaminofen/uso terapêutico , Avaliação da Tecnologia Biomédica , Colômbia
4.
s.l; IETSI; 27 mar. 2020.
Não convencional em Espanhol | LILACS, BRISA/RedTESA | ID: biblio-1096029

RESUMO

INTRODUCCIÓN: Uno de los medicamentos usados para aliviar la sintomatología causada por la infección del virus SARS-Cov-2 son los AINES (anti-inflamatorios no esteroideos). Estos fármacos se suelen indicar en caso de dolor de garganta, malestar general, que se encuentra dentro de la sintomatología del COVID19 descrita por la Organización Mundial de la Salud (OMS). Ante este escenario se planteó que el ibuprofeno o algún otro AINES, podría ser contraproducente en pacientes con COVID19 ya que los AINES, como el ibuprofeno, podrían incrementar la cantidad de receptores de ECA2 en las células humanas, haciendo más propenso al paciente hacer una infección por COVID19 (Fang, Karakiulakis, and Roth 2020). Por otro lado, los eventos adversos (EA) encontrados por el uso de ibuprofeno son alteraciones metabólicas propias de su mecanismo de acción al inhibir la adherencia plaquetaria producen incremento del tiempo de coagulación (TC), anemia, por lo que se debe monitorear la ocurrencia de este y otros EA. Para resolver estas dudas sobre el uso de AINES como ibuprofeno en el tratamiento de pacientes con COVID 19, encontramos los siguientes documentos. POSICIONES DE ENTIDADES INTERNACIONALES: En el pronunciamiento de la Organización Mundial de la Salud (OMS) y de la Organización Panamericana de la Salud (OPS) realizado el 18 de marzo 2020, se menciona que a la fecha no existe evidencia científica consistente que respalde el no uso de ibuprofeno u otros AINES en el manejo de pacientes con COVID19, dado que no se ha podido comprobar que agrave la enfermedad. Señala que se está buscando información al respecto y que no se tiene registro de que se incrementen los EA en pacientes con COVID19. Por tanto, no encuentra fundamento para que aquellos pacientes que ya reciben ibuprofeno abandonen su uso. Sin embargo, menciona que para aquellos pacientes que recién iniciarán terapia para aliviar los síntomas de COVID19, para ellos aconseja que se priorice el uso de paracetamol por sobre los AINES, incluido el ibuprofeno. La EMA establece que a la fecha no existe evidencia científica que respalde que los AINEs se asocien a mayor deterioro clínico de los pacientes con COVID-19. Señala que el Pharmacovigilance Risk Assessment Commitee (PRAC) de la EMA está recopilando información al respecto, desde mayo del 2019. La investigación se inició al conocerse los resultados de un análisis francés realizado por la French National Agency for La EMA establece que a la fecha no existe evidencia científica que respalde que los AINEs se asocien a mayor deterioro clínico de los pacientes con COVID-19. Señala que el Pharmacovigilance Risk Assessment Commitee (PRAC) de la EMA está recopilando información al respecto, desde mayo del 2019. La investigación se inició al conocerse los resultados de un análisis francés realizado por la French National Agency for Medicines and Health Products Safety (ANSM) 1 donde se propone que pacientes con infecciones virales (varicela) y bacteriana podrían deteriorar el curso clínico del paciente.. National Health System: Posición publicada al 20 de marzo del 2020, donde se recomienda que hasta que se publique nueva información científica al respecto, los pacientes con síntomas de coronavirus deben de recibir paracetamol como primera opción de tratamiento, por sobre ibuprofeno, siempre que el paciente no tenga contraindicación de uso de paracetamol. Además, indica que aquellos pacientes que ya vienen recibiendo ibuprofeno no es necesario que lo descontinúen. La información científica existente no es concluyente para determinar que existe un incremento de las complicaciones por COVID19 y el uso de ibuprofeno. Al momento, se ha designado a NICE (National Institute for Health and Care Excellence) una revisión de la evidencia al respecto. POSICIONES DE ENTIDADES NACIONALES: DIGEMID se pronuncia respecto al uso de ibuprofeno u algún otro AINEs como medicamento para tratar el dolor y la fiebre que se pueden producir en los pacientes con COVID-19. Al respecto señala que el paracetamol debería ser el medicamento de elección para contrarrestar los síntomas en COVID-19, en pacientes que recién presentan síntomas. En aquellos que vienen utilizando ibuprofeno u algún otro AINEs, no se encuentra fundamento para suspender su uso. Ante ello DIGEMID señala que esperarán que el informe del Pharmacovigilance Risk Assessment Commitee (PRAC) de la European Medicines Agency (EMA), para determinar la seguridad de AINEs como ibuprofeno y su relación con el deterioro cuando los pacientes tienen infecciones (dicho informe inició en mayo 2019). CONCLUSIÓNES: Por lo expuesto, al momento, no existe fundamento que avale que el ibuprofeno o algún otro AINES incremente la susceptibilidad de contraer COVID-19 o que el paciente haga la forma grave de la enfermedad. La OMS, OPS, EMA, NHS y DIGEMID no recomiendan suspender tratamiento con ibuprofeno o algún otro AINES si ya los están tomando. Sin embargo, mencionan también que, si una persona va a iniciar medicación, entonces priorice el uso de paracetamol sobre el de ibuprofeno (o a cualquier otro AINES) dado que la evidencia en general aun es escaza, y mientras se va estudiando el tema para llegar a un resultado más confiable.


Assuntos
Humanos , Ibuprofeno/efeitos adversos , Infecções por Coronavirus/tratamento farmacológico , Acetaminofen/uso terapêutico , Peru , Avaliação da Tecnologia Biomédica
5.
s.l; s.n; mar. 2020.
Não convencional em Espanhol | LILACS, BRISA/RedTESA | ID: biblio-1096637

RESUMO

CONTEXTO: En los últimos años, nuevas infecciones por coronavirus han surgido periódicamente en vários países del mundo. El coronavirus del síndrome respiratorio agudo severo (SARS-CoV) ocurrió em 2002, infectando a 8422 personas y causando 916 muertes durante la epidemia. El síndrome de coronavirus del Medio Oriente (MERS ­ CoV) se identificó por primera vez en 2012. Un total de 2499 casos fueron confirmados por laboratorio de MERS. A finales de 2019, un nuevo coronavirus surgió en Wuhan (China) y se extendió rápidamente. El patógeno se confirmó y fue nombrado oficialmente enfermedad por coronavirus ­ 19 (COVID ­ 19) por la Organización Mundial de la Salud (OMS). TECNOLOGÍA: El ibuprofeno es un AINE derivado del ácido propiónico. Es útil como analgésico-antipirético y presenta además actividad antiinflamatoria. El paracetamol o acetaminofén es un metabolito activo de la fenacetina. Es útil como analgésico-antipirético, con baja actividad antiinflamatoria. TECNOLOGÍAS ALTERNATIVAS: Los antipiréticos más utilizados en la práctica clínica cotidiana para atención de cuadros respiratorios suelen ser los AINES como el ibuprofeno y el paracetamol. De manera adicional, en población pediátrica en nuestro país es muy frecuente la utilización como antipirético de la dipirona. METODOLOGÍA:Se realizó una búsqueda no sistemática de bibliografía científica priorizando la inclusión de revisiones sistemáticas y metaanálisis, evaluaciones de tecnologías sanitarias e informes de seguridad, estudios de casos y controles y de cohortes prosp ectivas y retrospectivas, y Guías de Práctica Clínica basadas en la evidencia. RESULTADOS: No hay estudios sobre resultados con el uso de Ibuprofeno y Paracetamol en infecciones por COVID-19. Algunos estudios controlados y diversos estudios observacionales en adultos y niños con otras infecciones respiratorias agudas muestran un potencial mayor riesgo de complicaciones en pacientes con infecciones respiratorias agudas tratados con ibuprofeno comparado con paracetamol. Algunas recomendaciones de expertos sugieren el uso de Paracetamol en lugar de ibuprofeno en base a menor tasa de eventos adversos y menor tasa de nuevas consultas médicas. RECOMENDACIÓN: En favor de la utilización de paracetamol en lugar de ibuprofeno como agente antipirético en el contexto de pandemia por COVID-19 como tratamiento inicial. En personas con infección respiratoria de cualquier origen, el paracetamol probablemente tiene una efectividad similar a los AINES (como ibuprofeno) en el alivio de los síntomas y podría generar menos efectos adversos, principalmente gastrointestinales.


Assuntos
Humanos , Ibuprofeno/efeitos adversos , Infecções por Coronavirus/tratamento farmacológico , Acetaminofen/uso terapêutico , Avaliação da Tecnologia Biomédica , Análise Custo-Benefício
6.
Cochrane Database Syst Rev ; 1: CD004213, 2020 01 27.
Artigo em Inglês | MEDLINE | ID: mdl-31985838

RESUMO

BACKGROUND: Patent ductus arteriosus (PDA) complicates the clinical course of preterm infants and increases the risk of adverse outcomes. Indomethacin has been the standard treatment to close a PDA but is associated with renal, gastrointestinal, and cerebral side effects. Ibuprofen has less effect on blood flow velocity to important organs. OBJECTIVES: Primary objectives To determine the effectiveness and safety of ibuprofen compared to placebo/no intervention, or other cyclo-oxygenase inhibitor drugs in the prevention of PDA in preterm infants. SEARCH METHODS: We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 10), MEDLINE via PubMed (1966 to 17 October 2018), Embase (1980 to 17 October 2018), and CINAHL; 1982 to 17 October 2018). We searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. SELECTION CRITERIA: Randomised and quasi-randomised controlled trials comparing ibuprofen with placebo/no intervention or other cyclo-oxygenase inhibitor drugs to prevent PDA in preterm or low birth weight infants. DATA COLLECTION AND ANALYSIS: We extracted outcomes data including presence of PDA on day three or four of life (after 72 hours of treatment), need for surgical ligation or rescue treatment with cyclo-oxygenase inhibitors, mortality, cerebral, renal, pulmonary, and gastrointestinal complications. We performed meta-analyses and reported treatment estimates as typical mean difference (MD), risk ratio (RR), risk difference (RD) and, if statistically significant, number needed to treat to benefit (NNTB) or to harm (NNTH), along with their 95% confidence intervals (CI). We assessed between-study heterogeneity by the I-squared test (I²). We used the GRADE approach to assess the quality of evidence. MAIN RESULTS: In this updated analysis, we included nine trials (N = 1070 infants) comparing prophylactic ibuprofen (IV or oral) with placebo/no intervention or indomethacin. Ibuprofen (IV or oral) probably decreases the risk of PDA on day 3 or 4 (typical RR 0.39, 95% CI 0.31 to 0.48; typical RD -0.26, 95% CI -0.31 to -0.21; NNTB 4, 95% CI 3 to 5; 9 trials; N = 1029) (moderate-quality evidence). In the control group, the spontaneous closure rate was 58% by day 3 to 4 of age. In addition, ibuprofen probably decreases the need for rescue treatment with cyclo-oxygenase inhibitors (typical RR 0.17, 95% CI 0.11 to 0.26; typical RD -0.27, 95% CI -0.32 to -0.22; NNTB 4; 95% CI 3 to 5),and the need for surgical ductal ligation (typical RR 0.46, 95% CI 0.22 to 0.96; typical RD -0.03, 95% CI -0.05 to -0.00; NNTB 33, 95% CI 20 to infinity; 7 trials; N = 925) (moderate-quality evidence). There was a possible decrease in the risk of grade 3 or 4 intraventricular haemorrhage (IVH) in infants receiving prophylactic ibuprofen (typical RR 0.67, 95% CI 0.45 to 1.00; I² = 34%; typical RD -0.04, 95% CI -0.08 to- 0.00; I² = 60%; 7 trials; N = 925) (moderate-quality evidence). High quality evidence showed increased risk for oliguria (typical RR 1.45, 95% CI 1.04 to 2.02; typical RD 0.06, 95% CI 0.01 to 0.11; NNTH 17, 95% CI 9 to 100; 4 trials; N = 747). Low quality results from four studies (N = 202) showed that administering oral ibuprofen may decrease the risk of PDA (typical RR 0.47, 95% CI 0.30 to 0.74) and may increase risk of gastrointestinal bleeding (NNTH 7, 95% CI 4 to 25). No evidence of a difference was identified for mortality, any intraventricular haemorrhage (IVH), or chronic lung disease. AUTHORS' CONCLUSIONS: This review shows that prophylactic use of ibuprofen, compared to placebo or no intervention, probably decreases the incidence of patent ductus arteriosus, the need for rescue treatment with cyclo-oxygenase inhibitors, and for surgical ductal closure. Adverse effects associated with ibuprofen (IV or oral) included increased risks for oliguria, increase in serum creatinine levels, and increased risk of gastrointestinal haemorrhage. There was a reduced risk for intraventricular haemorrhage (grade III - IV) but no evidence of a difference in mortality, chronic lung disease, necrotising enterocolitis, or time to reach full feeds. In the control group, the patent ductus arteriosus had closed spontaneously by day 3 or 4 in 58% of neonates. Prophylactic treatment exposes a large proportion of infants unnecessarily to a drug that has important side effects without conferring any important short-term benefits. Current evidence does not support the use of ibuprofen for prevention of patent ductus arteriosus. Until long-term follow-up results of the trials included in this review have been published, no further trials of prophylactic ibuprofen are recommended. A new approach to patent ductus arteriosus management is an early targeted treatment based on echocardiographic criteria within the first 72 hours of life, that have a high sensitivity for diagnosing a patent ductus arteriosus that is unlikely to close spontaneously. Such trials are currently ongoing in many parts of the world. Results of such trials will be included in updates of our "Ibuprofen for treatment of PDA" review.


Assuntos
Inibidores de Ciclo-Oxigenase/uso terapêutico , Permeabilidade do Canal Arterial/prevenção & controle , Ibuprofeno/efeitos adversos , Ibuprofeno/uso terapêutico , Hemorragia Cerebral/induzido quimicamente , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Enterocolite Necrosante/induzido quimicamente , Inibidores Enzimáticos/uso terapêutico , Hemorragia Gastrointestinal/induzido quimicamente , Humanos , Indometacina/uso terapêutico , Recém-Nascido de Baixo Peso , Recém-Nascido , Recém-Nascido Prematuro , Ensaios Clínicos Controlados Aleatórios como Assunto
7.
Zhonghua Yu Fang Yi Xue Za Zhi ; 53(11): 1098-1103, 2019 Nov 06.
Artigo em Chinês | MEDLINE | ID: mdl-31683394

RESUMO

Objective: To describe the status of non-steroidal anti-inflammatory drugs (NSAIDs) use in areas with a high incidence of upper gastrointestinal cancer in China. Methods: This study was based on the National Key Research and Development Program of "National Precision Medicine Cohort of Esophageal Cancer" and "Study on Identification and Prevention of High-risk Populations of Gastrointestinal Malignancies (Esophageal cancer, Gastric cancer and Colorectal cancer)" . From January 2017 to August 2018, 212 villages or communities with a high incidence of esophageal cancer or gastric cancer were selected from 12 regions in 6 provinces. A total of 35 910 residents aged between 40 and 69 years old who met the inclusion criteria and signed the informed consent were investigated and enrolled in this study. The use of NSAIDs, demographic characteristics, health-related habits, height, weight, and blood pressure were collected by the questionnaire and physical examination. The status of main NSAIDs (aspirin, acetaminophen and ibuprofen) use with the difference varying in genders, age groups and regions were analyzed by using χ(2) test and Cochran-Armitage trend analysis method. Results: Of 35 910 subjects, the mean age was (54.6±7.1) years old and males accounted for 43.42% (15 591). The overall prevalence of NSAIDs intake was 4.56% (1 638), but it significantly varied in different provinces (P<0.001). The overall prevalence of NSAIDs intake was 4.87% (1 750) in females, which was significantly higher than that in males 4.24% (1 524) (P<0.001). The prevalence of NSAIDs intake increased with age (P for trend <0.001). As the frequency of NSAIDs intake increased, the incidence of gastrointestinal symptoms, gastrointestinal ulcers and black stools increased (P for trend <0.05 for all). Conclusion: The use of NSAIDs is prevalent in some areas with a high incidence of upper gastrointestinal cancer in China. The increased use of NSAIDs may lead to more adverse effects related to the gastrointestinal tract.


Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Anticarcinógenos/efeitos adversos , Aspirina/efeitos adversos , Neoplasias Gastrointestinais/epidemiologia , Ibuprofeno/efeitos adversos , Adulto , Idoso , Anti-Inflamatórios não Esteroides/farmacologia , Anticarcinógenos/farmacologia , Aspirina/farmacologia , China/epidemiologia , Estudos Transversais , Feminino , Neoplasias Gastrointestinais/induzido quimicamente , Neoplasias Gastrointestinais/etnologia , Humanos , Ibuprofeno/farmacologia , Incidência , Masculino , Pessoa de Meia-Idade , Inquéritos e Questionários
9.
Rev. Paul. Pediatr. (Ed. Port., Online) ; 37(3): 382-385, July-Sept. 2019. tab
Artigo em Inglês | LILACS | ID: biblio-1041340

RESUMO

ABSTRACT Objective: To report a case of a male adolescent with the diagnosis of ibuprofen-induced meningitis. We discuss themain causes of drug-induced aseptic meningitis (DIAM) and highlight the importance of early recognition of DIAM, sothat the offending drug can be withdrawn, and recurrences prevented. Only few DIAM cases have been reported in pediatric age. Case description: A healthy 15-year-old boy presented to the emergency department with headache, nausea, dizziness, fever, conjunctival hyperemia and blurred vision 30 minutes after ibuprofen-intake. During his stay, he developed emesis and neck stiffness. Cerebrospinal fluid analysis excluded infectious causes, and DIAM was considered. He totally recovered after drug withdrawal. Comments: DIAM is a rare entity, that should be considered in the differential diagnosis of an aseptic meningitis. The major causative agents are nonsteroidal anti-inflammatory drugs, particularly ibuprofen. Suspicion is made by the chronologic link between drug intake and the beginning of symptoms, but infectious causes should always be ruled out.


RESUMO Objetivo: Descreve-se o caso de um adolescente do sexo masculino com diagnóstico de meningite asséptica por ibuprofeno. Discutem-se as causas de meningite asséptica induzida por medicamentos (MAIM) e a importância do reconhecimento precoce dessa situação, para que a medicação envolvida seja suspensa e as recorrências prevenidas. Poucos casos foram descritos em idade pediátrica. Descrição do caso: Adolescente de 15 anos, gênero masculino, saudável, procurou o serviço de urgência por cefaleia, náuseas, tonturas, febre, hiperemia conjuntival e visão desfocada 30 minutos após o uso de ibuprofeno. Durante a internação, iniciou vômitos e rigidez na nuca. A análise do líquido cefalorraquidiano excluiu causas infeciosas, e considerou-se como diagnóstico mais provável a MAIM. A recuperação foi total após a suspensão do medicamento. Comentários: A MAIM é rara, mas deve ser considerada no diagnóstico diferencial de meningite asséptica. A principal causa são os anti-inflamatórios não esteroides, principalmente o ibuprofeno. A suspeita clínica é evocada pela relação temporal entre o uso do medicamento e o início dos sintomas, mas as causas infeciosas devem ser sempre excluídas.


Assuntos
Humanos , Masculino , Adolescente , Anti-Inflamatórios não Esteroides/efeitos adversos , Ibuprofeno/efeitos adversos , Meningite Asséptica/induzido quimicamente , Vômito , Resultado do Tratamento , Diagnóstico Diferencial , Hipersensibilidade a Drogas , Febre , Cefaleia , Meningite Asséptica/diagnóstico
10.
Ecotoxicology ; 28(6): 631-642, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31161525

RESUMO

Understanding the effects of many essential non-steroidal anti-inflammatory drugs (NSAIDs) on plants is still limited, especially at environmentally realistic concentrations. This paper presents the influence of three of the most frequently used NSAIDs (diclofenac, ibuprofen, and naproxen) at environmentally realistic concentrations on the autochthonous green leafy vegetables: orache (Atriplex patula L.), spinach (Spinacia oleracea L.) and lettuce (Lactuca sativa L.). Our research was focused on the determination of the photosynthetic parameters, the emission rate of volatile organic compounds, and the evaluation of the ultrastructure of leaves of studied vegetables after exposure to abiotic stress induced by environmental pollutants, namely NSAIDs. The data obtained indicate a moderate reduction of foliage physiological activity as a response to the stress induced by NSAIDs to the selected green leafy vegetables. The increase of the 3-hexenal and monoterpene emission rates with increasing NSAIDs concentration could be used as a sensitive and a rapid indicator to assess the toxicity of the NSAIDs. Microscopic analysis showed that the green leafy vegetables were affected by the selected NSAIDs. In comparison to the controls, the green leafy vegetables treated with NSAIDs presented irregular growth of glandular trichomes on the surface of the adaxial side of the leaves, less stomata, cells with less cytoplasm, irregular cell walls and randomly distributed chloroplasts. Of the three NSAIDs investigated in this study, ibuprofen presented the highest influence. The results obtained in this study can be used to better estimate the impact of drugs on the environment and to improve awareness on the importance of the responsible use of drugs.


Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Atriplex/efeitos dos fármacos , Poluentes Ambientais/efeitos adversos , Alface/efeitos dos fármacos , Fotossíntese/efeitos dos fármacos , Spinacia oleracea/efeitos dos fármacos , Compostos Orgânicos Voláteis/metabolismo , Atriplex/fisiologia , Atriplex/ultraestrutura , Diclofenaco/efeitos adversos , Ibuprofeno/efeitos adversos , Alface/fisiologia , Alface/ultraestrutura , Microscopia Eletrônica de Varredura , Microscopia Eletrônica de Transmissão , Naproxeno/efeitos adversos , Folhas de Planta/efeitos dos fármacos , Folhas de Planta/ultraestrutura , Spinacia oleracea/fisiologia , Spinacia oleracea/ultraestrutura
11.
Eur J Anaesthesiol ; 36(5): 351-359, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-30946703

RESUMO

BACKGROUND: NSAIDs and paracetamol are the cornerstones of pain treatment after day case surgery. However, NSAIDs have numerous contraindications and consequently are not suitable in up to 25% of patients. Metamizole is a non-opioid compound with a favourable gastro-intestinal and cardiovascular profile compared with NSAIDs. OBJECTIVES: The study aimed to assess if a combination of metamizole and paracetamol is noninferior to a combination of ibuprofen and paracetamol in treating pain at home after painful day case surgery. DESIGN: A double-blind randomised controlled trial. SETTING: Single centre. PATIENTS: Two hundred patients undergoing elective ambulatory haemorrhoid surgery, arthroscopic shoulder or knee surgery, or inguinal hernia repair. INTERVENTION: Patients were randomly allocated to receive either metamizole and paracetamol (n = 100) or ibuprofen and paracetamol (n = 100) orally for four days. MAIN OUTCOME MEASURES: Average postoperative pain intensity using a numerical rating scale and use of rescue medication were measured in the postanaesthesia care unit (PACU) and on postoperative days (POD) 1 to 3. A difference in mean numerical rating scale score of 1 point or less was considered noninferior. Adverse effects of study medication and satisfaction with study medication were measured on PODs 1 to 3 by telephone follow-up. RESULTS: In the PACU, the difference in mean ±â€ŠSD pain score between metamizole and paracetamol and ibuprofen and paracetamol was 0.85 ±â€Š0.78. From POD 1 to 3, this difference was lower than 1, resulting in noninferiority. Rescue opioid consumption in the PACU and on PODs 1 and 3 was not significantly different between treatment groups. Rescue opioid consumption on POD2 was significantly higher in the ibuprofen and paracetamol group (P = 0.042). Adverse effects of study medication and overall patient satisfaction were similar in both groups. CONCLUSION: Paracetamol/metamizole and paracetamol/ibuprofen are equally effective in treatment of acute postoperative pain at home after ambulatory surgery with comparable patient satisfaction levels. TRIAL REGISTRATION: European Union Clinical Trials Register 2015-003987-35.


Assuntos
Dor Aguda/tratamento farmacológico , Analgésicos não Entorpecentes/administração & dosagem , Dipirona/administração & dosagem , Ibuprofeno/administração & dosagem , Dor Pós-Operatória/tratamento farmacológico , Acetaminofen/administração & dosagem , Acetaminofen/efeitos adversos , Dor Aguda/diagnóstico , Dor Aguda/etiologia , Administração Oral , Adulto , Procedimentos Cirúrgicos Ambulatórios/efeitos adversos , Dipirona/efeitos adversos , Método Duplo-Cego , Quimioterapia Combinada/métodos , Feminino , Humanos , Ibuprofeno/efeitos adversos , Masculino , Pessoa de Meia-Idade , Medição da Dor , Dor Pós-Operatória/diagnóstico , Dor Pós-Operatória/etiologia , Satisfação do Paciente , Autoadministração , Resultado do Tratamento
12.
Paediatr Drugs ; 21(2): 113-121, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31025304

RESUMO

BACKGROUND: The ductus arteriosus (DA) is situated between the aortic arch and the pulmonary artery in fetal circulation, and its closure is one of the most important changes required for the transition to extrauterine life. Prolonged duration of patent DA (PDA) impairs hemodynamics and contributes both to morbidity associated with prematurity and to mortality. Therefore, when best to initiate treatment and what drug to use as first-line treatment to close the ductus is important. OBJECTIVE: The aim of this study was to compare the efficacy and side effects of the oral forms of ibuprofen and paracetamol and to contribute to the literature investigating the first drug to be selected in the medical treatment of PDA. METHODS: This observational, retrospective cohort study was conducted in infants born at ≤ 28 weeks' gestation and admitted to our Neonatal Intensive Care Unit (Manisa Merkezefendi State Hospital, Manisa, Turkey) between February 2015 and April 2018. Included infants were born at ≤ 28 weeks' gestation, had PDA-related clinical findings and hemodynamically significant PDA on echocardiography, and received oral ibuprofen or oral paracetamol therapy as the closure treatment. RESULTS: The most common clinical findings for the diagnosis of PDA were hyperdynamic circulation, tachycardia, and increased oxygen requirement. In total, 43 of the 51 (84.3%) premature infants in the ibuprofen group and 32 of the 36 (88.8%) in the paracetamol group achieved PDA closure after the first treatment cycle. There was no statistically significant difference between the two groups in terms of respiratory morbidity, renal and liver function, intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity, length of hospital stay, and mortality. CONCLUSIONS: Our results indicate that oral paracetamol was as effective as oral ibuprofen in the medical treatment of PDA. In addition, both drugs were considered well-tolerated in terms of effects on kidney, liver, and intestinal functions. Our results demonstrate that oral paracetamol can be used effectively and safely as the first-line treatment of PDA.


Assuntos
Acetaminofen/administração & dosagem , Analgésicos não Entorpecentes/administração & dosagem , Permeabilidade do Canal Arterial/tratamento farmacológico , Ibuprofeno/administração & dosagem , Recém-Nascido Prematuro , Acetaminofen/efeitos adversos , Administração Oral , Analgésicos não Entorpecentes/efeitos adversos , Permeabilidade do Canal Arterial/diagnóstico , Idade Gestacional , Hemodinâmica , Humanos , Ibuprofeno/efeitos adversos , Recém-Nascido de Baixo Peso , Recém-Nascido , Unidades de Terapia Intensiva Neonatal , Estudos Retrospectivos , Resultado do Tratamento
13.
Pharmacol Rep ; 71(2): 374-383, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30851540

RESUMO

Oxaceprol, a derivative of l-proline, is an established drug for managing osteoarthritis (OA) with better safety profile than non-steroidal anti-inflammatory drugs (NSAIDs). This systematic review and meta-analysis, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, evaluated the efficacy, safety and tolerability of oxaceprol in OA. Electronic databases for published and grey (unpublished) literature were searched to identify parallel-group randomized controlled trials (RCTs) evaluating the impact of oxaceprol in patients with OA. Risk of bias was assessed using the Cochrane collaboration's tool. A total of seven parallel-group RCTs involving 1087 participants were included in the systematic review. Meta-analysis, in Review Manager, demonstrated numerically greater/significant improvements compared to active control [diclofenac/ibuprofen]/placebo in pain and function of joint; similar improvement vs. active control in global treatment efficacy; no difference/significant difference vs. active control/placebo in NSAIDs as rescue medication. Treatment with oxaceprol showed numerically less adverse events (AEs) than active control (diclofenac: risk ratio [RR], 0.71; 95% confidence interval [CI], 0.45 to 1.11; p=0.14: ibuprofen: RR, 0.73; 95% CI, 0.30 to 1.78; p=0.49) and significantly fewer AEs compared to placebo (RR, 0.76; 95% CI, 0.63 to 0.92; p=0.004). Given the nature of small-to-moderate sample size and short duration of eligible studies, the available clinical evidence of oxaceprol in the management of OA is modest - though looks promising. New and better RCTs with larger sample size and longer follow-up are warranted to strengthen the use of oxaceprol in clinical setting for managing OA.


Assuntos
Antirreumáticos/uso terapêutico , Hidroxiprolina/uso terapêutico , Osteoartrite/tratamento farmacológico , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/efeitos adversos , Antirreumáticos/efeitos adversos , Diclofenaco/administração & dosagem , Diclofenaco/efeitos adversos , Humanos , Hidroxiprolina/efeitos adversos , Ibuprofeno/administração & dosagem , Ibuprofeno/efeitos adversos , Osteoartrite/fisiopatologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Tamanho da Amostra
14.
Am J Emerg Med ; 37(5): 924-927, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-30880039

RESUMO

OBJECTIVE: The primary purpose of this study was to identify the most common drug-drug interactions (DDI'S) in patients prescribed medications upon discharge from the emergency department. METHODS: We conducted a respective chart review of patients discharged home with a prescription from an academic emergency department. The study period was from August 1, 2015 to August 31, 2015. Patients will be excluded if they meet the following criteria: age under 20 years; discharge home without a prescription; inpatient hospital admission; transfer to another inpatient facility; or sign out against medical advice. The primary endpoint is the identification and characterization of drug-drug interactions caused by discharge prescriptions written by the treating physician. RESULTS: A total of 500 patient charts were included, with 38% having at least one DDI. Overall, there were 429 DDIs among 858 prescriptions written. 15.6% (n = 67) of the DDI's were classified as B, no modification of therapy needed. 60% (n = 260) of the DDIs were risk-rating category C, requiring monitoring of therapy. 22% (n = 95) of the DDI's identified were category D, which are consider modification of therapy. Lastly, we identified 1.6% (n = 7) category X DDI's. The top 3 most commonly associated drugs were oxycodone/acetaminophen, ibuprofen, and ciprofloxacin. CONCLUSION: DDIs are occurring upon discharge from a large, urban, tertiary care, academic medical center. Many of the DDI's identified do not require any modification to therapy. However, 23.6% of identified DDI's required modification or were contraindicated. A majority of the category X drug interactions involved QT prolongation.


Assuntos
Interações Medicamentosas , Serviço Hospitalar de Emergência , Alta do Paciente , Acetaminofen/efeitos adversos , Agonistas de Receptores Adrenérgicos beta 2/efeitos adversos , Adulto , Albuterol/efeitos adversos , Analgésicos/efeitos adversos , Ciprofloxacino/efeitos adversos , Combinação de Medicamentos , Feminino , Glucocorticoides/efeitos adversos , Humanos , Ibuprofeno/efeitos adversos , Masculino , Oxicodona/efeitos adversos , Prednisona/efeitos adversos , Estudos Retrospectivos
15.
Arthritis Rheumatol ; 71(8): 1225-1231, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-30801994

RESUMO

OBJECTIVE: While nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used in rheumatology, they can cause major toxicity. Improving the risk/benefit ratio requires a more precise understanding of risk. This study was undertaken to derive and validate a risk score for major toxicity among NSAID users enrolled in a randomized controlled trial. METHODS: Patients enrolled in a randomized controlled trial who had known cardiovascular disease or risk factors as well as osteoarthritis or rheumatoid arthritis were divided into derivation and validation cohorts. Patients were randomized to receive celecoxib, naproxen, or ibuprofen at typical dosages. The risk score was designed to predict the 1-year occurrence of major toxicity among NSAID users, including major adverse cardiovascular events, acute kidney injury, significant gastrointestinal events, and mortality. Variables significantly associated with major toxicity were candidates for inclusion in the final regression model. After derived models were found to have a similar model fit in the validation set, the cohorts were combined, allowing calculation of a risk score. RESULTS: In the derivation cohort, significant variables included age, male sex, history of cardiovascular disease, hypertension, diabetes mellitus, tobacco use, statin use, elevated serum creatinine level, hematocrit level, and type of arthritis. The C-index was 0.73 in the validation cohort and 0.71 in the total cohort; the model was well calibrated. Of the total population with complete data (n = 23,735), 1,080 participants (4.6%) had a predicted 1-year risk of major toxicity of <1%, 16,273 (68.6%) had a predicted risk of 1-4%, and 6,382 (26.9%) had a predicted risk of >4%. CONCLUSION: The risk score accurately categorizes the 1-year risk of major toxicity among NSAID users and may be useful in identifying patients who can safely use these agents.


Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/etiologia , Osteoartrite/tratamento farmacológico , Medição de Risco/estatística & dados numéricos , Idoso , Artrite Reumatoide/complicações , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/tratamento farmacológico , Celecoxib/efeitos adversos , Feminino , Humanos , Ibuprofeno/efeitos adversos , Masculino , Pessoa de Meia-Idade , Naproxeno/efeitos adversos , Osteoartrite/complicações , Reprodutibilidade dos Testes , Medição de Risco/métodos , Fatores de Risco
16.
JAMA ; 321(6): 562-571, 2019 02 12.
Artigo em Inglês | MEDLINE | ID: mdl-30747964

RESUMO

Importance: Multimodal postoperative analgesia is widely used but lacks evidence of benefit. Objective: Investigate beneficial and harmful effects of 4 nonopioid analgesics regimens. Design, Setting, and Participants: Randomized, blinded, placebo-controlled, 4-group trial in 6 Danish hospitals with 90-day follow-up that included 556 patients undergoing total hip arthroplasty (THA) from December 2015 to October 2017. Final date of follow-up was January 1, 2018. Interventions: Participants were randomized to receive paracetamol (acetaminophen) 1000 mg plus ibuprofen 400 mg (n = 136; PCM + IBU), paracetamol 1000 mg plus matched placebo (n = 142; PCM), ibuprofen 400 mg plus matched placebo (n = 141; IBU), or half-strength paracetamol 500 mg plus ibuprofen 200 mg (n = 140; HS-PCM + IBU) orally every 6 hours for 24 hours postoperatively, starting 1 hour before surgery. Main Outcomes and Measures: Two co-primary outcomes: 24-hour morphine consumption using patient-controlled analgesia in pairwise comparisons between the 4 groups (multiplicity-adjusted thresholds for statistical significance, P < .0042; minimal clinically important difference, 10 mg), and proportion of patients with 1 or more serious adverse events (SAEs) within 90 days (multiplicity-adjusted thresholds for statistical significance, P < .025). Results: Among 559 randomized participants (mean age, 67 years; 277 [50%] women), 556 (99.5%) completed the trial and were included in the analysis. Median 24-hour morphine consumption was 20 mg (99.6% CI, 0-148) in the PCM + IBU group, 36 mg (99.6% CI, 0-166) for PCM alone, 26 mg (99.6% CI, 2-139) for IBU alone, and 28 mg (99.6% CI, 2-145) for HS-PCM + IBU. The median difference in morphine consumption between the PCM + IBU group vs PCM alone was 16 mg (99.6% CI, 6.5 to 24; P < .001); for the PCM-alone group vs HS-PCM + IBU, 8 mg (99.6% CI, -1 to 14; P = .001); and for the PCM + IBU group vs IBU alone, 6 mg (99.6% CI, -2 to 16; P = .002). The difference in morphine consumption was not statistically significant for the PCM + IBU group vs HS-PCM + IBU (8 mg [99.6% CI, -2 to 16]; P = .005) or for the PCM-alone group vs IBU alone (10 mg [99.6% CI, -2 to 16]; P = .004) after adjustment for multiple comparisons and 2 co-primary outcomes. There was no significant difference between the IBU-alone group vs HS-PCM + IBU (2 mg [99.6% CI, -10 to 7]; P = .81). The proportion of patients with SAEs in groups receiving IBU was 15%, and in the PCM-alone group, was 11%. The relative risk of SAE was 1.44 (97.5% CI, 0.79 to 2.64; P = .18). Conclusions and Relevance: Among patients undergoing THA, paracetamol plus ibuprofen significantly reduced morphine consumption compared with paracetamol alone in the first 24 hours after surgery; there was no statistically significant increase in SAEs in the pooled groups receiving ibuprofen alone vs with paracetamol alone. However, the combination did not result in a clinically important improvement over ibuprofen alone, suggesting that ibuprofen alone may be a reasonable option for early postoperative oral analgesia. Trial Registration: ClinicalTrials.gov Identifier: NCT02571361.


Assuntos
Acetaminofen/administração & dosagem , Analgésicos não Entorpecentes/administração & dosagem , Analgésicos Opioides/administração & dosagem , Artroplastia de Quadril/efeitos adversos , Ibuprofeno/administração & dosagem , Morfina/administração & dosagem , Dor Pós-Operatória/tratamento farmacológico , Acetaminofen/efeitos adversos , Administração Oral , Idoso , Analgésicos não Entorpecentes/efeitos adversos , Analgésicos Opioides/efeitos adversos , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Humanos , Ibuprofeno/efeitos adversos , Masculino , Pessoa de Meia-Idade , Morfina/efeitos adversos , Medição da Dor
17.
Andrologia ; 51(4): e13228, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30623461

RESUMO

Ibuprofen is a widely used analgesic/antipyretic medication belongs to the nonsteroidal anti-inflammatory class. Even though the influence of ibuprofen on semen quality has been investigated in various occasions, the comprehensive understanding and discussion of its impact on semen quality is still yet to be determined. In this work, we systematically review and reveal the effect of ibuprofen on semen quality, and thus on fertilising capability. To achieve this goal, we searched the main research databases (Scopus and PubMed) from 1 June 1986 through 13 October 2018 for English-language articles and abstracts using the keywords "ibuprofen" versus "semen" and "sperm". In addition, related published articles or abstracts were also discussed if relevant. Altogether, the main stream of research, from both in vitro and in vivo studies, presents an adverse effect of ibuprofen on different sperm parameters such as motility, viability, count and DNA integrity; however, such effect is not yet confirmed in humans. Mechanisms by which ibuprofen affects semen quality may be by reducing testosterone and prostaglandin synthesis, chelating zinc ions and inhibiting nitric oxide synthesis. However, further research studies, mainly clinical, are still of great importance to confirm the effects of ibuprofen on semen quality.


Assuntos
Analgésicos não Entorpecentes/efeitos adversos , Ibuprofeno/efeitos adversos , Infertilidade Masculina/induzido quimicamente , Sêmen/efeitos dos fármacos , Humanos , Masculino , Óxido Nítrico/biossíntese , Prostaglandinas/biossíntese , Sêmen/metabolismo , Contagem de Espermatozoides , Motilidade Espermática/efeitos dos fármacos , Testosterona/biossíntese
18.
Pharmacology ; 103(3-4): 111-113, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30544105

RESUMO

To date, aspirin desensitization is employed with patients with nonsteroidal anti-inflammatory drugs (NSAIDs) exacerbated respiratory diseases (NERD) or with aspirin or NSAIDs hypersensitive patients needing a stent procedure for coronary artery disease. On the other hand, few data exist regarding aspirin desensitization in other cardiological features and particularly we haven't data on different NSAIDs desensitization. Only for NERD patients we have data on ketorolac use. We report an efficacious desensitization procedure for ibuprofen in urticaria/angioedema patient with pericarditis and myocarditis associated.


Assuntos
Anti-Inflamatórios não Esteroides/administração & dosagem , Dessensibilização Imunológica/métodos , Hipersensibilidade a Drogas/prevenção & controle , Ibuprofeno/administração & dosagem , Miocardite/tratamento farmacológico , Adulto , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/imunologia , Esquema de Medicação , Hipersensibilidade a Drogas/diagnóstico , Hipersensibilidade a Drogas/imunologia , Humanos , Ibuprofeno/efeitos adversos , Ibuprofeno/imunologia , Masculino , Miocardite/diagnóstico , Miocardite/imunologia , Resultado do Tratamento
19.
Int Arch Allergy Immunol ; 178(2): 177-181, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30544107

RESUMO

BACKGROUND: Ibuprofen is the most frequently used over-the-counter nonsteroidal anti-inflammatory drug (NSAID) in North America. While it has been commonly implicated in drug-induced hypersensitivity reactions, there is limited literature specifically on ibuprofen hypersensitivity. OBJECTIVES: To characterize the demographics and clinical course of hypersensitivity reactions in a cohort of patients with ibuprofen allergy. METHODS: A retrospective chart review of patients diagnosed with ibuprofen allergy was conducted between 2008 and 2016 in an allergy clinic at a tertiary care academic institution. Demographics and clinical information were obtained, and severity of reactions was assessed by a standardized grading system. RESULTS: A total of 41 patients were included of whom 27 were female. The mean age at first reaction to ibuprofen was 33 ± 13.9 years. The medi an time from the first reaction to the time of diagnosis was 1 year (0-3). The median time from ibuprofen exposure to the onset of symptoms was 30 min (16-101). The median duration of symptoms was 180 min (60-1,440). Urticaria and angioedema were seen in 90% of patients. The reactions were either mild (46%) or moderate (51%) in severity, but 1 patient had severe anaphylaxis. Cross-reactivity to other NSAIDs or acetaminophen was seen and presented with mostly mild reactions. CONCLUSION: In our cohort of patients, ibuprofen hypersensitivity affected females more commonly than males, and presented with mainly cutaneous manifestations. Onset of symptoms was rapid (< 60 min). Reactions typically ranged in severity from mild to moderate although there was a risk of severe anaphylaxis. There was potential cross-reactivity with other NSAIDs or acetaminophen. The results of our study contribute to the understanding of the demographics and clinical course of ibuprofen hypersensitivity reactions.


Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Hipersensibilidade a Drogas/diagnóstico , Hipersensibilidade a Drogas/imunologia , Ibuprofeno/efeitos adversos , Adulto , Reações Cruzadas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Especificidade de Órgãos/imunologia , Estudos Retrospectivos , Índice de Gravidade de Doença , Testes Cutâneos , Avaliação de Sintomas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA